Larry L. Wood - 08 Nov 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, TAVR
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 Nov 2022
Net transactions value
-$229,921
Form type
4
Filing time
08 Nov 2022, 17:01:25 UTC
Previous filing
11 Oct 2022
Next filing
13 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $266,144 +7,242 +3.6% $36.75 209,474 08 Nov 2022 Direct F1
transaction EW Common Stock Sale $496,065 -7,242 -3.5% $68.50 202,232 08 Nov 2022 Direct F1, F2
holding EW Common Stock 496 08 Nov 2022 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -7,242 -50% $0.000000 7,236 08 Nov 2022 Common Stock 7,242 $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $68.195 to $68.595. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.